1. Home
  2. WHF vs WHWK Comparison

WHF vs WHWK Comparison

Compare WHF & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WHF

WhiteHorse Finance Inc.

HOLD

Current Price

$7.60

Market Cap

164.5M

Sector

Finance

ML Signal

HOLD

WHWK

Whitehawk Therapeutics Inc.

HOLD

Current Price

$4.17

Market Cap

179.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WHF
WHWK
Founded
2011
2007
Country
United States
United States
Employees
3
22
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.5M
179.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WHF
WHWK
Price
$7.60
$4.17
Analyst Decision
Sell
Strong Buy
Analyst Count
2
2
Target Price
$7.75
$7.50
AVG Volume (30 Days)
99.7K
211.2K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
13.64%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.07
$1.39
52 Week High
$9.95
$4.40

Technical Indicators

Market Signals
Indicator
WHF
WHWK
Relative Strength Index (RSI) 58.41 65.12
Support Level $6.80 $1.84
Resistance Level $7.62 $4.40
Average True Range (ATR) 0.21 0.28
MACD 0.00 0.07
Stochastic Oscillator 69.86 81.82

Price Performance

Historical Comparison
WHF
WHWK

About WHF WhiteHorse Finance Inc.

WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.

About WHWK Whitehawk Therapeutics Inc.

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

Share on Social Networks: